Solventum Raises 2026 Profit Outlook Despite Sales Drop

The medical device maker lifted its adjusted earnings guidance even as third-quarter sales fell 7% from a year earlier.

Updated on Nov. 6, 2026 in Corporate Finance

Solventum Raises 2026 Profit Outlook Despite Sales Drop

Solventum reported third-quarter sales of $1.95bn, down 7% from a year earlier, as customers worked through about $125m in orders pulled forward ahead of its largest-ever ERP cutover. The company still raised its 2026 adjusted EPS guidance and reported adjusted EPS of $1.45.

Why it matters

The order pull-forward and system transition distort the quarter's headline sales decline, while the raised guidance signals management's confidence in the underlying business. Its separation from 3M, now more than 90% complete, marks a major step in the company's standalone operations for U.S. investors tracking the stock.

Solventum reported third-quarter sales of $1.95bn, down 7% from a year earlier, and adjusted EPS of $1.45, with about $125m in orders pulled forward ahead of its ERP cutover. The article does not quantify how much of the sales decline will reverse in later quarters.

The players

Solventum

Solventum is a medical technology company spun off from 3M that focuses on healthcare products and services.

Bryan Hanson

Bryan Hanson is the chief executive officer of Solventum, leading the company through its separation from 3M.

The details

Solventum's sales fell as customers worked through orders pulled forward ahead of the company's largest-ever ERP cutover, which moved its order and accounting systems off 3M's platforms onto Solventum's own. Despite the weaker top line, the company raised its 2026 adjusted EPS guidance, and its separation from 3M is more than 90% complete.

Third quarter of 2026: sales fell 7% year over year amid pulled-forward orders.
May 2026: CEO Bryan Hanson discussed working with a buyer on the exit of the Health Information Systems business.

Market Dynamics

Solventum's standalone transition follows 3M's decision to separate its healthcare business into an independent public company. The ERP cutover and guidance raise show how spin-offs are judged on operational execution as much as on headline sales trends.

Investors holding Solventum shares should weigh the raised adjusted EPS guidance against the 7% sales decline and the timing of the pulled-forward orders. The company's dividend and buyback plans are not addressed in the article.

The takeaway

Headline sales can understate or overstate a quarter when customers move orders across periods, so investors should look at guidance and order timing together. Solventum's ability to execute its ERP cutover will be a key test of its standalone readiness.